ARGX

argenx SE American Depositary Receipt (ARGX) | Rumor.io

argenx

ARGX

Attention (50-day avg)0%

Attention rank (50-day avg)#853

Bullish sentiment (50-day avg)68%

Price to earnings ratio36.5

Market capitalization60.5B

Earnings per share26.3

Dividend yield (TTM)—

Revenue (annual)4.2B

Net income (annual)1.3B

Social

What share of all stock conversation is about ARGX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% +0

Aug 26

UBS upgrades $ARGX to "Buy" with a price target of $1,400, citing the company's strong sales and EPS growth.
Wells Fargo maintains its Overweight rating on $ARGX with a price target of $1,415, based on the company's upcoming Phase 3 trial in multifocal motor neuropathy.
$ARGX shares trade higher after UBS and Wells Fargo upgrade their ratings, with the former citing institutional sponsorship and the latter emphasizing the company's strong growth momentum.

Generated by AI

Sentiment

Of the messages about ARGX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% +32.08	80.76% -12.07
Bearish	—	0% 0	0% -32.08	19.24% +12.07

Dec 20

Analysts at Raymond James and Wells Fargo have raised their price targets for argenx, to $455 and $395 respectively, citing the company's strong potential.
Credit Suisse has also raised its price target for argenx to $340, although maintaining a neutral rating.
Analysts are optimistic about argenx's prospects, with several maintaining strong buy or overweight ratings, and one analyst predicting it could become one of the top 10 selling medicines in the next decade.

Generated by AI

Topics

Of the messages about ARGX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	22.73%	15.76%	56.19%
Technical Analysis	0%	77.27%	29.09%	7.85%
Analysts	0%	0%	29.09%	15.78%
Macro	0%	0%	26.06%	17.99%
Earnings	0%	0%	0%	2.1%
Controversies	0%	0%	0%	0.07%

Earnings· Oct 25

ARGX is set to release earnings before the market opens on Thursday.
Analysts expect ARGX to report an EPS of -0.46.
The release of earnings is expected to occur on Thursday.

Analysts· Aug 26

UBS has upgraded argenx SE's (ARGX) stock rating to "Buy" from "Neutral" and raised its price target to $1,400.
Wells Fargo has maintained its "Overweight" rating on argenx SE, with a price target increased to $1,415 from $1,350.
UBS views argenx SE's upcoming Phase 3 trial in multifocal motor neuropathy as adequately de-risked, with a modeled 65% probability of success.

Announcements· Aug 17

Argenx SE (ARGX) announced positive topline results from the Phase 3 ALKIVIA trial of efgartigimod in autoimmune myositis, with the study meeting its primary endpoint of a statistically significant improvement in mean Total Improvement Score.
The Phase 3 ALKIVIA trial of efgartigimod in autoimmune myositis achieved a 15.4-point greater improvement in Total Improvement Score versus placebo, with the combined IMNM/DM population meeting the primary endpoint.
Argenx's VYVGART Hytrulo achieved a significant improvement in mean Total Improvement Score in the Phase 3 ALKIVIA trial, with the company's shares up roughly 17% intraday as investors treat this as a meaningful expansion opportunity for the VYVGART franchise.

Generated by AI

Community

Of the messages about ARGX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	88.51%	80.48%	25.49%
Newcomers	0%	11.49%	19.52%	74.51%

Regulars· Aug 17

argenx SE (ARGX) announces positive topline results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis, meeting the primary endpoint with a 15.4-point improvement in TIS at Week 52.
The trial showed a significant improvement in TIS, a key measure of muscle function, with patients receiving efgartigimod experiencing a 15.4-point improvement at Week 52 compared to placebo.
The news sends ARGX stock soaring, with a new ATH (all-time high) of $977.84, as investors react to the positive topline results and the potential for efgartigimod to become a treatment for autoimmune myositis.

Newcomers· Aug 26

Newcomers to $ARGX are focused on its Phase 2 to Phase 3 transition, which is expected to drive long-term growth.
The company's deep clinical pipeline, with 10 active trials, is a key catalyst for its stock, with a potential 76% conviction from long-term investors.
New analysts are maintaining an Overweight rating on $ARGX, with a price target increase to $1415, citing the upcoming Phase 3 trial in multifocal motor neuropathy as a key de-risking factor.

Generated by AI

News

Here's Exactly Why Wall Street Thinks Argenx Stock Could Soar 23% Over the Next 12 Months | The Motley Fool

There are good reasons behind analyst's bullish views of this biotech stock.

4d agoThe Motley Fool

Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today - argenx (NASDAQ:ARGX)

argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 14.22% on an annualized basis producing an average annual return of 26.19%. Currently, argenx has a market capitalization of $59.17 billion.

5d agoBenzinga

Vyvgart’s expanding pipeline supports argenx’s long-term sales potential

5d agospglobal.com

argenx (ENXTBR:ARGX) Shares Moved, So What Is Drawing Attention Now?

argenx (ENXTBR:ARGX) drew fresh attention after its Extraordinary General Meeting confirmed Thomas M. Brakel and Khurem Farooq as new non-executive directors, prompting investors to reassess how board composition might influence longer term decision making. argenx shares trade at €835.8 after a modest pullback, with the 30-day share price return down 3.29%. The 90-day move is up 6.91%, and the year-to-date share price return is 15.47%, while the 1-year total shareholder return sits at 34.37%...

6d agoYahoo Finance

Argenx, Arrowhead, Incyte, and Other ‘Moonshot’ Biotech Stocks to Watch

7d agoBarron's

2 Wall Street Analysts Think Argenx Can Soar More Than 40%. Here's Why They're Right.

10d agoYahoo Finance

Also Discussed

Investors talking about ARGX also mention

#	Name	Attention
1	Galapagos NV American Depositary ReceiptGLPG	0%0
2	AGRX - Agile Therapeutics, Inc.	——
3	MRUS - Merus N.V.	——
4	Zai Lab Limited ADRZLAB	0%0
5	Immunovant Inc.IMVT	0%0
6	Genmab A/S American Depositary SharesGMAB	0%0
7	Biohaven Ltd.BHVN	0%-0.01
8	BPMC - Blueprint Medicines Corporation	——
9	MRTX - Mirati Therapeutics, Inc.	——
10	Alnylam Pharmaceuticals, Inc.ALNY	0%0

argenx SE American Depositary Receipt

Healthcare
Biotechnology

argenx SE American Depositary Receipt is an American depositary receipt representing shares of argenx SE, a Netherlands-based biopharmaceutical company focused on developing and commercializing antibody-based therapies for severe autoimmune and neuromuscular diseases. The company’s current portfolio centers on immunology medicines, including treatments for generalized myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy. argenx also advances a broader pipeline of differentiated antibody therapeutics built on its proprietary Simple Antibody platform, which supports research across autoimmune and other specialty disease areas. As an ADR, it gives U.S. market participants a way to access argenx’s underlying equity exposure through a familiar U.S.-traded security. The asset is closely tied to the global biotechnology and healthcare markets, where demand for specialized biologic therapies continues to shape commercial and clinical activity.

Website

Location

Laarderhoogtweg 25

Amsterdam, 1101 EB

Netherlands

Social

What share of all stock conversation is about ARGX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% +0

Aug 26

UBS upgrades $ARGX to "Buy" with a price target of $1,400, citing the company's strong sales and EPS growth.
Wells Fargo maintains its Overweight rating on $ARGX with a price target of $1,415, based on the company's upcoming Phase 3 trial in multifocal motor neuropathy.
$ARGX shares trade higher after UBS and Wells Fargo upgrade their ratings, with the former citing institutional sponsorship and the latter emphasizing the company's strong growth momentum.

Generated by AI

Sentiment

Of the messages about ARGX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% +32.08	80.76% -12.07
Bearish	—	0% 0	0% -32.08	19.24% +12.07

Dec 20

Analysts at Raymond James and Wells Fargo have raised their price targets for argenx, to $455 and $395 respectively, citing the company's strong potential.
Credit Suisse has also raised its price target for argenx to $340, although maintaining a neutral rating.
Analysts are optimistic about argenx's prospects, with several maintaining strong buy or overweight ratings, and one analyst predicting it could become one of the top 10 selling medicines in the next decade.

Generated by AI

Topics

Of the messages about ARGX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	22.73%	15.76%	56.19%
Technical Analysis	0%	77.27%	29.09%	7.85%
Analysts	0%	0%	29.09%	15.78%
Macro	0%	0%	26.06%	17.99%
Earnings	0%	0%	0%	2.1%
Controversies	0%	0%	0%	0.07%

Earnings· Oct 25

ARGX is set to release earnings before the market opens on Thursday.
Analysts expect ARGX to report an EPS of -0.46.
The release of earnings is expected to occur on Thursday.

Analysts· Aug 26

UBS has upgraded argenx SE's (ARGX) stock rating to "Buy" from "Neutral" and raised its price target to $1,400.
Wells Fargo has maintained its "Overweight" rating on argenx SE, with a price target increased to $1,415 from $1,350.
UBS views argenx SE's upcoming Phase 3 trial in multifocal motor neuropathy as adequately de-risked, with a modeled 65% probability of success.

Announcements· Aug 17

Argenx SE (ARGX) announced positive topline results from the Phase 3 ALKIVIA trial of efgartigimod in autoimmune myositis, with the study meeting its primary endpoint of a statistically significant improvement in mean Total Improvement Score.
The Phase 3 ALKIVIA trial of efgartigimod in autoimmune myositis achieved a 15.4-point greater improvement in Total Improvement Score versus placebo, with the combined IMNM/DM population meeting the primary endpoint.
Argenx's VYVGART Hytrulo achieved a significant improvement in mean Total Improvement Score in the Phase 3 ALKIVIA trial, with the company's shares up roughly 17% intraday as investors treat this as a meaningful expansion opportunity for the VYVGART franchise.

Generated by AI

Community

Of the messages about ARGX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	88.51%	80.48%	25.49%
Newcomers	0%	11.49%	19.52%	74.51%

Regulars· Aug 17

argenx SE (ARGX) announces positive topline results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis, meeting the primary endpoint with a 15.4-point improvement in TIS at Week 52.
The trial showed a significant improvement in TIS, a key measure of muscle function, with patients receiving efgartigimod experiencing a 15.4-point improvement at Week 52 compared to placebo.
The news sends ARGX stock soaring, with a new ATH (all-time high) of $977.84, as investors react to the positive topline results and the potential for efgartigimod to become a treatment for autoimmune myositis.

Newcomers· Aug 26

Newcomers to $ARGX are focused on its Phase 2 to Phase 3 transition, which is expected to drive long-term growth.
The company's deep clinical pipeline, with 10 active trials, is a key catalyst for its stock, with a potential 76% conviction from long-term investors.
New analysts are maintaining an Overweight rating on $ARGX, with a price target increase to $1415, citing the upcoming Phase 3 trial in multifocal motor neuropathy as a key de-risking factor.

Generated by AI

argenx

Social

Aug 26

Dec 20

Earnings· Oct 25

Analysts· Aug 26

Announcements· Aug 17

Regulars· Aug 17

Newcomers· Aug 26

Here's Exactly Why Wall Street Thinks Argenx Stock Could Soar 23% Over the Next 12 Months | The Motley Fool

Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today - argenx (NASDAQ:ARGX)

Vyvgart’s expanding pipeline supports argenx’s long-term sales potential

argenx (ENXTBR:ARGX) Shares Moved, So What Is Drawing Attention Now?

Argenx, Arrowhead, Incyte, and Other ‘Moonshot’ Biotech Stocks to Watch

2 Wall Street Analysts Think Argenx Can Soar More Than 40%. Here's Why They're Right.

Also Discussed

argenx SE American Depositary Receipt

Company Information

Location

Here's Exactly Why Wall Street Thinks Argenx Stock Could Soar 23% Over the Next 12 Months | The Motley Fool

Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today - argenx (NASDAQ:ARGX)

Vyvgart’s expanding pipeline supports argenx’s long-term sales potential

argenx (ENXTBR:ARGX) Shares Moved, So What Is Drawing Attention Now?

Argenx, Arrowhead, Incyte, and Other ‘Moonshot’ Biotech Stocks to Watch

2 Wall Street Analysts Think Argenx Can Soar More Than 40%. Here's Why They're Right.

Also Discussed

Social

Aug 26

Dec 20

Earnings· Oct 25

Analysts· Aug 26

Announcements· Aug 17

Regulars· Aug 17

Newcomers· Aug 26